Lactobacillus reuteri DSM 17938 high dose

Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: A randomized controlled trial. (Diabetes Obes Metab, 2017) [PMID:28009106]
The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938. (J Physiol, 2015) [PMID:26084409]

_Worker-drafted node — pending editorial review._

Connections